Rapid Therapeutic Science Laboratories, Inc.
RTSL · OTC
12/31/2024 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.03 | 0.00 | -0.45 |
| FCF Yield | 0.00% | -1.38% | -20.39% | -6.73% |
| EV / EBITDA | -1,016.60 | 158.06 | -54.12 | -316.71 |
| Quality | ||||
| ROIC | -2.59% | 4.23% | -32.41% | 2.49% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.16 | -0.22 | -7.19 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 97.10% | 35.52% | -136.50% |
| Safety | ||||
| Net Debt / EBITDA | -1,016.60 | 138.56 | -40.72 | -125.84 |
| Interest Coverage | -0.37 | -0.35 | -0.89 | 0.39 |
| Efficiency | ||||
| Inventory Turnover | 0.03 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -559.76 | 0.00 | 0.00 | 0.00 |